Oragenics Inc. has filed a Form 8-K to provide additional information about the acquisition of the Neurology Assets from Odyssey Health, Inc. The acquisition is expected to focus the company's resources on the development of neurology assets, primarily ONP-002, a drug candidate for treating mild traumatic brain injury and Niemann Pick Disease Type C. The filing also includes information about the expected impact on the company's business, the payment made for the acquisition, and the appointment of Michael Redmond as President of Oragenics.